0001145549-20-001226.txt : 20200113 0001145549-20-001226.hdr.sgml : 20200113 20200113151034 ACCESSION NUMBER: 0001145549-20-001226 CONFORMED SUBMISSION TYPE: N-CEN PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20191031 FILED AS OF DATE: 20200113 DATE AS OF CHANGE: 20200113 EFFECTIVENESS DATE: 20200113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Series Portfolios Trust CENTRAL INDEX KEY: 0001650149 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: N-CEN SEC ACT: 1940 Act SEC FILE NUMBER: 811-23084 FILM NUMBER: 20523730 BUSINESS ADDRESS: STREET 1: 615 E. MICHIGAN STREET CITY: MILWAUKEE STATE: WI ZIP: 53202 BUSINESS PHONE: 414-765-6620 MAIL ADDRESS: STREET 1: 615 E. MICHIGAN STREET CITY: MILWAUKEE STATE: WI ZIP: 53202 0001650149 S000051293 Weiss Alternative Balanced Risk Fund C000161708 Class A C000161709 Investor Class WEIZX C000161710 Class I WEISX C000161711 Class K WEIKX 0001650149 S000055426 Rareview Longevity Income Generation Fund C000174406 Retail Class RLIGX C000174407 Institutional Class RVIGX 0001650149 S000060157 MProved Systematic Long-Short Fund C000196894 Investor Class MLSJX C000196895 Institutional Class MLSQX 0001650149 S000061416 Equable Shares Small Cap Fund C000198889 Class I EQSIX 0001650149 S000061417 Equable Shares Large Cap Fund C000198890 Class I EQLIX N-CEN 1 primary_doc.xml X0201 N-CEN LIVE 0001650149 XXXXXXXX false false false N-1A S000061417 true S000061416 true S000060157 true S000055426 true S000051293 true Series Portfolios Trust 811-23084 0001650149 5493008VNHP5UNYJ3713 615 East Michigan Street Milwaukee 53202 US-WI US 4147656839 U.S. Bank National Association Custody Operations 1555 North River Center Drive Suite 302 Milwaukee 53212 18336121912 Custody data Weiss Multi-Strategy Advisers LLC 320 Park Avenue 20th Floor New York 10022 18665302690 Adviser data for WEIKX & WEIZX U.S. Bancorp Fund Services, LLC 615 E. Michigan Street Milwaukee 53202 18336121912 Transfer agency, fund accounting and fund administration data Quasar Distributors, LLC 777 East Wisconsin Avenue Milwaukee 53202 18336121912 Distribution data Teramo Advisors, LLC 1016 Collier Center Way Suite 106 Naples 34110 18336121912 Adviser data for EQLIX and EQSIX Heitman Real Estate Securities, LLC 191 North Wacker Drive Chicago 60606 18887992944 Adviser data for HTMIX and HTMNX Magnetar Asset Management, LLC 1603 Orrington Avenue 13th Floor Evanston 60201 18336776833 Adviser data for MMSQX, MMSJX, MMAQX, and MMAJX Oakhurst Advisors, LLC 1875 Century Park East Suite 960 Los Angeles 90067 18446254778 Adviser data for OASDX Palm Valley Capital Management LLC 422 Jacksonville Drive Jacksonville Beach 32250 18667473111 Adviser data for PCVMX Rareview Capital LLC 1266 East Main Street Suite 700R Stamford 06902 18446254778 Adviser data for RVIGX & RLIGX N N N N-1A 8 Y Koji Felton N/A N Debra McGinty- Poteet 002908931 N Daniel B. Wiley N/A N Dana L. Armour N/A Y Jennifer E. Kienbaum N/A 615 E. Michigan Street Milwaukee 53202 XXXXXX N Donna M. Barrette N/A 622 N Cass Street Milwaukee 53202 XXXXXX N N N N N N N Y Cohen & Company, Ltd. 00925 N/A Ernst & Young LLP 00042 N/A N N N N N N N Equable Shares Large Cap Fund S000061417 54930001L5DJYVXHSW79 Y 1 0 0 N/A Y N Y N N/A N/A N/A Rule 12d1-1 (17 CFR 270.12d1-1) Rule 32a-4 (17 CFR 270.32a-4) Y Y Y N Teramo Advisors, LLC 801-112238 000291574 N/A N U.S. Bancorp Fund Services, LLC 85-11357 N1GZ7BBF3NP8GI976H15 Y N N Intercontinental Exchange Inc. 5493000F4ZO33MV32P92 N Bloomberg L.P. 549300B56MD0ZC402L06 N IHS Markit Ltd. 549300HLPTRASHS0E726 BM N Thomson Reuters Pricing Service N/A CA N PricingDirect Inc. 549300WIC0TOJ7N7GD54 N N U.S. Bank National Association 6BYL5QZYBDK8S7L73M02 Y N Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) N N U.S. Bancorp Fund Services, LLC N1GZ7BBF3NP8GI976H15 Y N N Merrill Lynch Professional Clearing Corp. 8-33359 000016139 549300PMHS66E71I2D34 2657.000000000000 Merrill Lynch, Pierce, Fenner & Smith Incorporated 8-7221 000007691 8NAV47T0Y26Q87Y0QP81 156.000000000000 2813.000000000000 0.000000000000 N 13964093.000000000000 N N Rareview Longevity Income Generation Fund S000055426 549300CVNKSGMB7QYD85 N 2 0 0 Fund of Funds N N N N N/A N/A N/A Rule 12d1-1 (17 CFR 270.12d1-1) Rule 32a-4 (17 CFR 270.32a-4) Y Y Y N Rareview Capital, LLC 801-108100 000284474 549300CVNKSGMB7QYD85 N U.S. Bancorp Fund Services, LLC 85-11357 N1GZ7BBF3NP8GI976H15 Y N N Intercontinental Exchange Inc. 5493000F4ZO33MV32P92 N Bloomberg L.P. 549300B56MD0ZC402L06 N IHS Markit Ltd. 549300HLPTRASHS0E726 BM N Thomson Reuters Pricing Service N/A CA N PricingDirect Inc. 549300WIC0TOJ7N7GD54 N N U.S. Bank National Association 6BYL5QZYBDK8S7L73M02 Y N Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) N N U.S. Bancorp Fund Services, LLC N1GZ7BBF3NP8GI976H15 Y N N Sanders Morris Harris LLC 8-38325 000020580 N/A 25498.000000000000 Jonestrading Institutional Services LLC 8-26089 000006888 2138008JJ5PA8H5UIL69 18736.000000000000 Interactive Brokers LLC 8-47257 000036418 50OBSE5T5521O6SMZR28 60859.000000000000 UBS Financial Services Inc 8-16267 000008174 ETYRV6ORNFJB5NONI676 12394.000000000000 TD Securities (USA) LLC 8-36747 000018476 SUVUFHICNZMP2WKHG940 25792.000000000000 Wallachbeth Capital LLC 8-67936 000147853 549300R371KUKXEXC133 16734.000000000000 160013.000000000000 TD Securities (USA) LLC 8-36747 000018476 SUVUFHICNZMP2WKHG940 174306.000000000000 174306.000000000000 N 19214592.000000000000 N N Weiss Alternative Balanced Risk Fund S000051293 5493004TYL1WK8HQHE93 N 4 0 0 N/A N N Y N N/A N/A N/A Rule 12d1-1 (17 CFR 270.12d1-1) Rule 32a-4 (17 CFR 270.32a-4) Y Y Y N Weiss Multi-Strategy Advisers LLC 801-71151 000136150 549300NX0B5LQB7GKH98 N U.S. Bancorp Fund Services, LLC 85-11357 N1GZ7BBF3NP8GI976H15 Y N N Intercontinental Exchange Inc. 5493000F4ZO33MV32P92 N Bloomberg L.P. 549300B56MD0ZC402L06 N IHS Markit Ltd. 549300HLPTRASHS0E726 BM N Thomson Reuters Pricing Service N/A CA N PricingDirect Inc. 549300WIC0TOJ7N7GD54 N N U.S. Bank National Association 6BYL5QZYBDK8S7L73M02 Y N Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) BNP Paribas Securities Services (BNP) 549300WCGB70D06XZS54 GB N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) The Bank of New York Mellon HPFHU0OQ28E4N0NFVK49 N Y Foreign securities depository - rule 17f-7 (17 CFR 270.17f-7) Banco Nacional de Mexico S.A. (Banamex) 2SFFM4FUIE05S37WFU55 MX N Y Foreign securities depository - rule 17f-7 (17 CFR 270.17f-7) Svenska Handelsbanken AB (publ) NHBDILHZTYCNBV5UYZ31 SE N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) Royal Bank of Canada ES7IP3U3RHIGC71XBU11 CA N Y Foreign securities depository - rule 17f-7 (17 CFR 270.17f-7) N N U.S. Bancorp Fund Services, LLC N1GZ7BBF3NP8GI976H15 Y N N BMO Harris Financial Advisor, Inc. 8-67064 000137115 N/A 75375.000000000000 Evercore Group L.L.C. 8-49830 000042405 5493008F0LRLS5N8LZ81 19103.000000000000 Morgan Stanley & Co. LLC 8-15869 000008209 9R7GPTSO7KV3UQJZQ078 74541.000000000000 J.P. Morgan Securities LLC 8-35008 000000079 ZBUT11V806EZRVTWT807 45458.000000000000 Goldman Sachs & Co. LLC 8-12900 000000361 FOR8UP27PHTHYVLBNG30 39960.000000000000 Merrill Lynch Professional Clearing Corp. 8-33359 000016139 549300PMHS66E71I2D34 38556.000000000000 Barclay Capital Inc. 8-41342 000019714 AC28XWWI3WIBK2824319 36906.000000000000 Credit Suisse Securities (USA) LLC 8-42200 000000816 1V8Y6QCX6YMJ2OELII46 28036.000000000000 Jefferies LLC 8-15074 000002347 58PU97L1C0WSRCWADL48 27574.000000000000 Citigroup Global Markets, Inc. 8-81770 000007059 MBNUM2BPBDO7JBLYG310 25300.000000000000 685319.000000000000 Morgan Stanley & Co., Inc. 8-15869 000008209 9R7GPTSO7KV3UQJZQ078 20843570.000000000000 BNP Paribas Brokerage Services, Inc. 8-40490 000024962 7VHWWWW4UJS7NUM3PT30 1600367.000000000000 Goldman Sachs & Co. 8-12900 000000361 FOR8UP27PHTHYVLBNG30 13536610.000000000000 Deutsche Bank Trust Co. 8-17822 000002525 9J6MBOOO7BECTDTUZW19 13319066.000000000000 J.P Morgan Chase 8-35008 000000079 ZBUT11V806EZRVTWT807 6930623.000000000000 Bank of America N.A. 8-33359 000016139 549300PMHS66E71I2D34 6238561.000000000000 Credit Suisse 8-42200 000000816 1V8Y6QCX6YMJ2OELII46 4897811.000000000000 Marketaxess Corp. 8-50727 000044542 GPSMMRI21JE7ZCVYF972 3573795.000000000000 Barclay Investments Ltd. 8-41342 000019714 AC28XWWI3WIBK2824319 2282035.000000000000 Wells Fargo Bank N.A. 8-65876 000126292 VYVVCKR63DVZZN70PB21 2197917.000000000000 89554673.000000000000 N 89993218.000000000000 N N true INTERNAL CONTROL RPT 2 internalcontrolrprt_33.htm INTERNAL CONTROL LETTER FOR RAREVIEW & EQUABLE. FOR VALIDATION PURPOSES ONLY - [815912.G1AIII_33]

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Trustees of Series Portfolios Trust

In planning and performing our audit of the financial statements Equable Shares Large Cap Fund and Rareview Longevity Income Generation Fund (the “Funds”), each a series of Series Portfolios Trust, as of and for the periods ended October 31, 2019, in accordance with the standards of the Public Company Accounting Oversight Board (United States), we considered the Funds’ internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an opinion on the effectiveness of the Funds’ internal control over financial reporting. Accordingly, we express no such opinion.

The management of the Funds is responsible for establishing and maintaining effective internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls. A fund’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles (GAAP). A fund’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the fund; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the fund are being made only in accordance with authorizations of management and trustees of the fund; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a fund’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Funds’ annual or interim financial statements will not be prevented or detected on a timely basis.

Our consideration of the Funds’ internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control that might be material weaknesses under standards established by the Public Company Accounting Oversight Board (United States). However, we noted no deficiencies in the Funds’ internal control over financial reporting and its operation, including controls over safeguarding securities that we consider to be a material weakness as defined above as of October 31, 2019.

This report is intended solely for the information and use of management and the Board of Trustees of the Funds and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties.

COHEN & COMPANY, LTD.

Milwaukee, Wisconsin

December 23, 2019

INTERNAL CONTROL RPT 3 internalconrolrprt_34.htm INTERNAL CONTROL LETTER FOR WEISS. FOR VALIDATION PURPOSES ONLY - [815912.G1AIII_34]

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders of Weiss Alternative Balanced Risk Fund and

Board of Trustees of Series Portfolios Trust

In planning and performing our audit of the financial statements of Weiss Alternative Balanced Risk Fund (the “Fund”), a series of Series Portfolios Trust, as of and for the year ended October 31, 2019, in accordance with the standards of the Public Company Accounting Oversight Board (United States), we considered the Fund’s internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an opinion on the effectiveness of the Fund’s internal control over financial reporting. Accordingly, we express no such opinion.

The management of the Fund is responsible for establishing and maintaining effective internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls. A fund’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles (GAAP). A fund’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the fund; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the fund are being made only in accordance with authorizations of management and trustees of the fund; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a fund’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Fund’s annual or interim financial statements will not be prevented or detected on a timely basis.

Our consideration of the Fund’s internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control that might be material weaknesses under standards established by the Public Company Accounting Oversight Board (United States). However, we noted no deficiencies in the Fund’s internal control over financial reporting and its operation, including controls over safeguarding securities, that we consider to be a material weakness as defined above as of October 31, 2019.

This report is intended solely for the information and use of management and the Board of Trustees of the Fund and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties.

COHEN & COMPANY, LTD.

Milwaukee, Wisconsin

December 30, 2019